Tofacitinib

Drug Profile

Tofacitinib

Alternative Names: Cp-690-550; CP-690550; Jaquinus; Tasocitinib; Tofacitinib citrate; Xeljanz; Xeljanz XR

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator Pfizer
  • Developer Johns Hopkins University; Pfizer
  • Class 2 ring heterocyclic compounds; Amides; Nitriles; Piperidines; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Immunosuppressants; Janus kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Rheumatoid arthritis
  • Phase III Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Ulcerative colitis
  • Phase II Atopic dermatitis
  • Phase I Dermatomyositis
  • Discontinued Ankylosing spondylitis; Asthma; Crohn's disease; Dry eyes; Irritable bowel syndrome; Renal transplant rejection

Most Recent Events

  • 27 Jan 2017 The CHMP of the European Medicines Agency (EMA) adopts a positive opinion recommending tofacitinib for Rheumatoid arthritis (PO)
  • 01 Jan 2017 Phase-I clinical trials in Dermatomyositis (Treatment-resistant) in USA (PO) (NCT03002649)
  • 19 Dec 2016 Pfizer plans a phase III trial for Juvenile rheumatoid arthritis (Adjunctive treatment) in USA (PO, Tablet) (NCT03000439)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top